What Is the Newest Treatment for Scleroderma?

CAR T-cell therapy, a treatment that reprograms a patient’s own immune cells to hunt down disease-driving B cells, represents the newest and most experimental frontier in scleroderma treatment. Early case series published in 2024 and 2025 report striking improvements in skin thickening and lung function in small numbers of patients with severe disease. But the treatment landscape for scleroderma has shifted substantially in recent years even beyond CAR T cells, with newly approved drugs for lung involvement, promising trial data on rituximab for skin disease, and several drug classes still working through clinical trials. The honest picture is that there is no single “newest treatment” but rather a wave of options reaching patients at different stages of testing.

CAR T-Cell Therapy for Severe Scleroderma

The most attention-grabbing development in scleroderma research is the use of CD19-targeted CAR T-cell therapy, adapted from blood cancer treatment. In this approach, a patient’s T cells are collected, genetically modified to recognize and destroy CD19-positive B cells, and infused back. The rationale is that B cells drive the autoantibody production and inflammatory signaling that fuel scleroderma’s fibrosis.

A case series published in The Lancet Rheumatology followed six patients with severe diffuse scleroderma who received CAR T-cell therapy. Over a median follow-up of roughly 16 months, skin thickening scores dropped by about 31% within the first 100 days, and all patients reached the highest probability of clinical improvement on a composite disease measure by six months. No serious safety events occurred during the observation period.¹

A separate report on five patients who were unsuitable for stem cell transplant showed that CAR T cells expanded quickly after infusion, effectively depleted CD19-positive B cells within a week, and allowed all patients to stop immunosuppressive medications after discharge. Disease-specific autoantibodies declined and, in some patients, temporarily disappeared. B cells did begin returning around three months, but there were no clinical signs of disease flare.²

These results are exciting, but they come with serious caveats. The total number of scleroderma patients treated with CAR T cells worldwide is still in the low dozens. There are no randomized controlled trials, no long-term follow-up beyond about two years, and no way yet to know who will respond best. The therapy also requires specialized centers and carries risks including cytokine release syndrome, which can be life-threatening. For now, CAR T-cell therapy sits firmly in the experimental category, available mainly through clinical trials or compassionate use programs.

Approved Drugs for Scleroderma Lung Disease

The organ complication that has seen the most concrete treatment progress is interstitial lung disease, which affects a large proportion of scleroderma patients and is a leading cause of death. Two drugs now have regulatory approval specifically for scleroderma-associated lung disease, and both work by slowing the decline in lung capacity rather than reversing existing damage.

Nintedanib

Nintedanib, an antifibrotic drug originally developed for idiopathic pulmonary fibrosis, was approved for scleroderma-associated interstitial lung disease based on the SENSCIS trial. In that trial, patients on nintedanib lost about 52 ml of lung capacity per year compared to about 93 ml per year on placebo, a difference of roughly 41 ml per year.³ Patients who were also taking mycophenolate as background therapy fared even better, with a lung capacity decline of only about 40 ml per year compared to roughly 64 ml per year among those not on background therapy.⁴ Nintedanib does not improve lung function or reverse fibrosis. It slows the worsening, which matters a great deal when lung damage is progressive and irreversible. Gastrointestinal side effects, especially diarrhea, are common.

Tocilizumab

Tocilizumab, an antibody that blocks the interleukin-6 receptor, was approved for scleroderma-associated interstitial lung disease after a phase 3 trial showed it preserved lung function over 48 weeks. The drug did not have a statistically significant effect on skin thickening, but it slowed lung decline compared to placebo.⁵ A systematic review and meta-analysis found that patients receiving tocilizumab were nearly twice as likely to see any increase in lung capacity compared to placebo, and the risk of losing more than 10% of lung function was reduced by about two-thirds.⁶ Real-world data comparing tocilizumab with rituximab in a separate cohort found that both drugs stabilized lung function, with tocilizumab showing a particular benefit in patients positive for anti-topoisomerase antibodies.⁷

Rituximab for Skin and Lung Disease

Rituximab, a B-cell-depleting antibody long used in other autoimmune conditions, has emerged as one of the most promising treatments for scleroderma skin thickening, which has historically been one of the hardest aspects of the disease to treat. The Japanese DESIRES trial was the first randomized controlled trial to show clear efficacy for skin sclerosis as the primary endpoint. Patients who received rituximab saw their skin scores drop substantially, while those on placebo worsened. The difference between the two groups at 24 weeks was striking.⁸

The open-label extension of that trial showed sustained improvement. Patients who continued rituximab for a second course kept improving through 48 weeks, and patients who crossed over from placebo to rituximab also improved once they started the active drug.⁹ Longer follow-up showed that lung function also gradually improved, reaching statistical significance after three courses of treatment.¹⁰

Rituximab is not yet approved specifically for scleroderma in most countries, but it is increasingly used off-label by scleroderma specialists, especially for patients with progressive skin or lung disease who have not responded to first-line immunosuppressants. The DESIRES results have been a turning point in convincing the field that targeting B cells can make a real difference in skin fibrosis.

Autologous Stem Cell Transplant

For patients with rapidly progressive diffuse disease and significant organ involvement, autologous hematopoietic stem cell transplant remains the most aggressive option with the strongest survival data from randomized trials. The approach involves collecting a patient’s own stem cells, wiping out the immune system with high-dose chemotherapy, and then reinfusing the stem cells to rebuild an immune system that, ideally, no longer attacks the patient’s own tissues.

The landmark SCOT trial compared transplant to monthly intravenous cyclophosphamide. At six years, event-free survival was about 74% in the transplant group versus 47% with cyclophosphamide, and overall survival was about 86% versus 51%.¹¹ A Cochrane review of the transplant trials confirmed improved event-free survival, though it noted that no single trial demonstrated a clear overall mortality benefit in the primary analysis, and transplant-related mortality was roughly 3–6% in the first several years.¹²

That treatment-related mortality is the reason transplant is reserved for patients with severe, rapidly worsening disease who have enough cardiac and pulmonary reserve to survive the procedure. It is not a treatment offered lightly, and careful patient selection is everything. Among patients with rapidly progressive disease and interstitial lung disease, transplant has become one of the most effective disease-modifying strategies available.¹³

ROCK2 Inhibitors and JAK Inhibitors in the Pipeline

Two drug classes currently making their way through clinical testing could eventually expand the treatment toolkit for scleroderma in meaningful ways.

ROCK2 inhibitors target a signaling pathway involved in both inflammation and the excessive tissue remodeling that drives fibrosis. In mouse models of scleroderma, a selective ROCK2 inhibitor reduced skin thickening and lung fibrosis by shifting the balance of immune cells away from pro-inflammatory types.¹⁴ Belumosudil, a ROCK2 inhibitor already approved for chronic graft-versus-host disease, is being tested in an open-label trial in patients with diffuse scleroderma.¹⁵ Having an existing approval for another fibrotic condition gives this class a head start in terms of known safety data, but results in scleroderma are still preliminary.

JAK inhibitors, which block another set of intracellular signaling pathways, have shown promise across several autoimmune diseases. A systematic review concluded that they could be a safe and effective option for both skin fibrosis and lung disease in scleroderma.¹⁶ A retrospective study of tofacitinib, one of the more widely available JAK inhibitors, found that it improved skin sclerosis and early radiological lung abnormalities in scleroderma patients with interstitial lung disease.¹⁷ Small studies also suggest JAK inhibitors may help treat digital ulcers, one of scleroderma’s most painful complications.¹⁸ Neither drug class is yet approved for scleroderma, and large randomized trials are still needed.

Sotatercept for Pulmonary Arterial Hypertension

Scleroderma can cause pulmonary arterial hypertension, a dangerous increase in blood pressure within the lung’s arteries that strains the heart. Sotatercept, a drug that works by rebalancing signaling pathways involved in blood vessel remodeling, was approved for pulmonary arterial hypertension in general and is now being studied specifically in scleroderma patients.

Early clinical data look encouraging. A study of scleroderma patients with both pulmonary arterial hypertension and interstitial lung disease found that 24 weeks of sotatercept produced substantial improvements: pulmonary vascular resistance dropped by roughly 42%, the distance patients could walk in six minutes increased by about 64%, and a key heart strain marker fell by more than half. Supplemental oxygen needs also decreased significantly.¹⁹ A separate case report described benefit even in a patient with a particularly dangerous subtype of pulmonary vascular disease associated with scleroderma, though treatment had to be interrupted due to rising hemoglobin levels, a known side effect of the drug’s mechanism.²⁰

For patients whose scleroderma is dominated by pulmonary arterial hypertension rather than lung fibrosis, sotatercept may represent the most meaningful recent addition to treatment options.

Why Early Treatment Matters More Than the Specific Drug

One of the most practically important findings in recent scleroderma research is that when you start treatment may matter as much as which treatment you choose. A study comparing early versus delayed initiation of immunomodulatory therapy found that patients who started treatment within 18 months of their first non-Raynaud’s symptom were more likely to see their skin and lung disease improve, while those who started later were more likely to remain stable but not improve. Disease activity scores improved more in the early group, and disease severity stayed stable rather than worsening.²¹

The interpretation is that scleroderma has a window of opportunity when the disease is still in its inflammatory, immune-driven phase and has not yet locked in irreversible fibrosis. Immunosuppressive drugs work better during this early window because there are still active immune processes to suppress. Once fibrosis is established, the damage becomes structural and harder to reverse with any existing drug. This is a strong argument for aggressive early evaluation and treatment in newly diagnosed patients with diffuse disease, even when symptoms still seem manageable.

Managing Digital Ulcers

Digital ulcers, the painful sores that develop on the fingertips and around the nails due to impaired blood flow, remain one of scleroderma’s most debilitating day-to-day complications. There are still no FDA-approved medications specifically for digital ulcers in the United States.²² A systematic review covering nearly 2,600 patients found that intravenous iloprost (a prostacyclin), phosphodiesterase-5 inhibitors, and atorvastatin are effective for treating active ulcers, while bosentan can reduce the rate of new ulcers forming.¹⁸ In practice, treatment often combines vasodilators with wound care, and the goal is a mix of healing current ulcers and preventing new ones.

Fat Grafting for Facial and Hand Involvement

One of the less discussed but genuinely useful advances is autologous fat grafting for facial and hand involvement. Scleroderma tightens the skin around the mouth, limiting how wide patients can open it, and stiffens the hands. Fat grafting involves taking a patient’s own fat tissue and injecting it into the affected area. Unlike many scleroderma treatments, the goal here is direct functional improvement rather than suppressing the underlying disease.

A study of perioral fat injections found that facial handicap scores improved by about 35% at six months, mouth opening increased, and skin sclerosis around the mouth improved by roughly 65–80% at three months.²³ Another study confirmed that fat grafting improved perioral skin quality, facial animation, hand range of motion, and hand pain.²⁴ About 80% of patients in a third study rated their aesthetic and functional results as satisfying.²⁵

Fat grafting does not alter the course of scleroderma itself. It does not suppress fibrosis or change autoantibody levels. But for patients whose quality of life is heavily affected by facial tightness or hand stiffness, it can provide meaningful functional gains that systemic drugs do not address. The procedure is minimally invasive and uses the patient’s own tissue, minimizing rejection risk.

How Autoantibodies Are Guiding Treatment Choices

Scleroderma is not a single disease so much as a cluster of overlapping patterns, and the specific autoantibodies a patient carries are increasingly being used to predict which organs are at risk and which treatments are most likely to work. Different antibody profiles are associated with different risks: some predict severe lung fibrosis, others predict pulmonary arterial hypertension, and others suggest a milder course overall.²⁶ The real-world tocilizumab and rituximab comparison mentioned earlier found that patients positive for anti-topoisomerase antibodies responded particularly well to tocilizumab for lung disease, hinting that antibody profiles could help guide drug selection.⁷

This kind of precision-medicine thinking is still in its early stages for scleroderma. Most treatment decisions are still made based on which organs are involved and how quickly the disease is progressing. But as more data accumulate linking specific biomarkers to treatment response, the field is moving toward a model where two patients with the same organ involvement might receive different drugs based on their antibody and cytokine profiles.

Juvenile Scleroderma Is a Different Clinical Problem

Children and adolescents who develop scleroderma present differently from adults. Juvenile-onset patients are more likely to have the diffuse form of the disease but tend to have better overall survival than adults.²⁷ Treatment for juvenile scleroderma borrows heavily from adult approaches but differs in some areas, including the use of corticosteroids, which play a more accepted role in children than in adult scleroderma. An expert consensus panel has emphasized that management of juvenile scleroderma requires its own treatment framework rather than simply applying adult protocols to younger patients.²⁸ Pediatric rheumatology centers are the appropriate setting for these patients, and families should not assume that findings from adult drug trials apply directly to children.